Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239069 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT01239069 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 140 participants.
The verdict
NCT01239069, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease
Interventions
- OTHER Placebo
- DRUG DE-110 ophthalmic suspension high dose
- DRUG DE-110 ophthalmic suspension low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239069
The ClinicalTrials.gov registry entry for NCT01239069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01239069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01239069 about?
NCT01239069 is a clinical study titled "Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease". Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease
What is the current status of trial NCT01239069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2010-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01239069?
The interventions under investigation include: Placebo (OTHER), DE-110 ophthalmic suspension high dose (DRUG), DE-110 ophthalmic suspension low dose (DRUG).
Who is sponsoring clinical trial NCT01239069?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.